Methocarbamol


Full Prescribing Info
Dosage/Direction for Use

Oral
Painful muscle spasm associated with musculoskeletal conditions
Adult: Initially: 1.5 g 4 times daily, reduced according to response after 2-3 days. Maintenance: 2.25-4 g daily in divided doses. Max dose 8 g daily.
Elderly: Dose may need to be reduced by half.

Intravenous

Painful muscle spasm associated with musculoskeletal conditions
Adult: 1 g administered by slow inj or infusion at a rate not faster than 300 mg/min. In cases where patients are not able to continue with oral therapy, additional doses of 1 g every 8 hr may be used for up to 3 consecutive days. Max 3 g daily.
Elderly: Dose may need to be reduced by half.

Intramuscular

Painful muscle spasm associated with musculoskeletal conditions
Adult: Up to 500 mg into each gluteal region at intervals of 8 hr. In cases where patients are not able to continue with oral therapy, additional doses of 1 g every 8 hr may be used for up to consecutive 3 days. Max 3 g daily.
Elderly: Dose may need to be reduced by half.

Intravenous

Tetanus
Adult: Initial total dose: 3 g with 1-2 g via direct inj at a rate of 300 mg/minute and the remainder 1-2 g may be administered via infusion. Repeat infusion of 1-2 g every 6 hr until a nasogastric tube can be inserted. Tablets may be crushed and suspended in water or saline solutions and administered through the nasogastric tube. Total oral dosage of up to 24 g daily may be needed.
Child: 15 mg/kg or 500 mg/m2 given by IV inj (suggested rate 180 mg/m2/min). Dose may be repeated every 6 hr if necessary by IV inj or infusion. Max dose 1.8 g/m2 daily for 3 consecutive days.
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Contraindications
Coma or pre-coma states, brain damage, myasthenia gravis Do not admin parenteral solutions in patients with renal impairment, epilepsy or history of epilepsy.
Special Precautions
Renal or hepatic impairment; acidosis. Pregnancy and lactation. May impair ability to drive or operate machinery. Children ≤12 yr.
Adverse Reactions
Nausea, anorexia, lassitude, drowsiness, dizziness, restlesness, anxiety, confusion, fever, headache, blurred vision, convulsions; hypersensitivity reactions e.g. rashes, pruritus, urticaria, angiodema. Parenteral: Flushing and a metallic taste; incoordination, diplopia, nystagmus, vertigo; sloughing and thrombophloebitis at the site of inj.
Potentially Fatal: Parenteral: Syncope, hypotension, bradycardia, anaphylaxis.
Overdosage
Manage with symptomatic and supportive treatment.
Drug Interactions
Action potentiated by alcohol and other CNS depressants. May inhibit effect of pyridostigmine, use with caution with anticholinesterase agents.
Lab Interference
May cause colour interference in screening tests for 5-hydroxyindoleacetic acid using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid using the Gitlow method.
Action
Methocarbamol is a centrally acting skeletal muscle relaxant whose precise mode of action is not known. It is said to cause general depression of the central nervous system.
Absorption: Rapidly and almost completely absorbed from the GI tract. Peak plasma concentration in 1-2 hr (oral).
Distribution: Plasma protein boumd 46-50%. Crosses placenta.
Metabolism: Metabolised by dealkylation and hydroxylation.
Excretion: Via urine as metabolites and unchanged drug. 1-2 hr (elimination half-life).
Storage
Intramuscular: Store at 20-25°C Intravenous: Store at 20-25°C Oral: Store at 20-25°C
CIMS Class
ATC Classification
M03BA03 - methocarbamol ; Belongs to the class of carbamic esters. Used as centrally-acting muscle relaxants.
Disclaimer: This information is independently developed by CIMS based on methocarbamol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in